uniQure CEO Matthew Kapusta Purchases Company Shares
CEO Matthew Kapusta bought 4,128 shares of uniQure N.V. at $31.71 each.
Key Points
- Matthew Kapusta, CEO of uniQure N.V., purchased 4,128 shares at $31.71 per share, totaling $130,898.88 on June 24, 2026.
- uniQure N.V., traded on NasdaqGS under ticker QURE, has a market cap of approximately $3.38 billion and a 52-week high of $71.50.
- Analysts maintain a strong buy consensus with a mean target price of $61.59, reflecting optimism in uniQure's future prospects.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Matthew Kapusta, the CEO and Managing Director of uniQure N.V., made a significant purchase of company shares on June 24, 2026. Kapusta acquired 4,128 shares at an average price of $31.71 each, amounting to a total investment of $130,898.88. This transaction was not part of a pre-arranged trading plan.
Insider Buying and Selling at uniQure N.V.
On June 24, 2026, Matthew Kapusta, CEO and Managing Director of uniQure N.V., bought 4,128 shares at $31.71 each, totaling $130,898.88. The transaction was not made under a Rule 10b5-1 plan. Additionally, on June 25, 2026, Kapusta executed several transactions, including selling 28,716 shares at $50.02 per share as part of a planned sale.
uniQure N.V. Stock Down 2.5%
Shares of NasdaqGS:QURE traded near $47.84 on Saturday. uniQure N.V., a biotechnology firm based in Amsterdam, Netherlands, has a market cap of about $3.38 billion. The company is not currently profitable, which means it has no meaningful P/E ratio. With a beta of 1.001, the stock has shown a 52-week range between $8.73 and $71.50. The company's 50-day moving average stands at $26.62, while the 200-day moving average is $28.13.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Mizuho maintained its buy rating on uniQure N.V. with a price target of $68. Barclays upgraded the stock to a buy rating with a $65 target on June 18, 2026. Goldman Sachs, on the same day, maintained a hold rating with a $46 target. The consensus among analysts is a strong buy, with a mean target price of $61.59, based on 11 opinions.
About uniQure N.V.
uniQure N.V. is a biotechnology company focused on developing treatments for rare and severe diseases. Headquartered in Amsterdam, Netherlands, it offers HEMGENIX for hemophilia B and is advancing gene therapy candidates like AMT-130 for Huntington's disease. The company employs 221 people and is led by CEO Matthew Craig Kapusta.
Bottom Line
Matthew Kapusta's recent purchase of uniQure shares is a notable insider activity that investors might watch. uniQure operates in the biotechnology sector, developing innovative therapies for rare diseases. The company's stock is closely monitored, with analysts maintaining a strong buy consensus. Remember, insider transactions are reported after the fact and may not indicate future stock performance.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.